Prescient Therapeutics Targets $7 Million SPP to Propel PTX-100 Development
Prescient Therapeutics launches a $7 million Share Purchase Plan at an 18.8% discount to fund advancement of its PTX-100 cancer therapy beyond a key 2026 Dose Optimisation Committee review.
- SPP priced at $0.065 per share, 18.8% discount to 10-day VWAP
- Funds to advance PTX-100 past Dose Optimisation Committee in H2 2026
- SPP open to eligible shareholders with $30,000 maximum participation
- Potential follow-on placement to sophisticated investors post-SPP
- PTX-100 holds FDA Orphan and Fast Track designations for T-cell lymphomas
Capital Raise Supports Next Phase for PTX-100
Melbourne-based Prescient Therapeutics (ASX:PTX) has announced a Share Purchase Plan (SPP) aiming to raise $7 million at $0.065 per share, representing an 18.8% discount to the 10-day volume weighted average price. The capital injection is earmarked to push its lead oncology candidate, PTX-100, beyond a pivotal Dose Optimisation Committee review targeted for the second half of 2026. This milestone is critical as it precedes further clinical development stages and regulatory engagement.
The SPP offers eligible shareholders the chance to invest up to $30,000 each, with share allotments expected to be finalised by mid-September. Prescient also retains the option to conduct a follow-on placement to sophisticated and professional investors if demand exceeds the SPP capacity.
PTX-100’s Clinical Progress and Regulatory Momentum
PTX-100 is a first-in-class inhibitor targeting geranylgeranyl transferase-1 (GGTase-1), a key enzyme involved in oncogenic Ras pathways implicated in up to 22% of cancers. The drug has demonstrated safety and encouraging efficacy signals in prior Phase 1 and 1b studies, particularly in T-cell lymphomas. The US FDA has granted PTX-100 Orphan Drug Designation for all T-cell lymphomas and Fast Track Designation for relapsed or refractory mycosis fungoides, the most common subtype of Cutaneous T-cell lymphoma (CTCL).
Currently, a Phase 2a trial is recruiting globally to enroll up to 40 patients, aiming to generate data to support regulatory approval and broader patient access. The SPP proceeds will help sustain this clinical momentum and fund general working capital, business development, and potential pipeline expansion.
Broader Pipeline and Shareholder Engagement
Beyond PTX-100, Prescient is developing innovative cell therapy platforms including OmniCAR, a modular CAR-T system enabling multi-antigen targeting, and CellPryme technologies designed to enhance CAR-T cell efficacy and persistence. These programs remain in preclinical or early-stage development but represent potential future value drivers.
To engage shareholders, CEO James McDonnell will host a live briefing on 28 August 2026 to discuss the SPP details and company strategy. This outreach comes as the company balances advancing clinical programs with prudent capital management amid a competitive biotech landscape.
While the SPP is a standard mechanism to bolster funds, the timing and size reflect a cautious but optimistic approach to progressing PTX-100 through critical clinical milestones. The outcome of the Dose Optimisation Committee review and subsequent trial results will be key catalysts to watch.
Bottom Line?
Prescient’s $7 million SPP underscores a strategic push to advance PTX-100 through a crucial 2026 clinical review, setting the stage for potential regulatory progress amid ongoing development risks.
Questions in the middle?
- Will the Dose Optimisation Committee review validate PTX-100’s clinical potential and unlock further funding?
- How might the company balance advancing PTX-100 with its broader cell therapy platforms in a capital-constrained environment?
- What level of shareholder uptake and follow-on placement demand will signal confidence in Prescient’s growth trajectory?
